Effects of repaglinide and sitagliptin on daily glucose swing and endothelial function: an open-label parallel-group randomized trial
Not Applicable
- Conditions
- type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000009988
- Lead Sponsor
- The University of Tokushima Graduate School of Health Biosciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1.Hypoglycemia unawareness or recurrent major hypoglycaemia 2.Known severe liver disease 3.Known or suspected allergy to trial products or related products 4.Pregnant or planning to become pregnant within the next 12 months, breast-feeding 5.Any condition that the Investigator or Sponsor feel would interfere with trial participation or evaluation of results 6.Not provided written informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method continuous glucose monitor (CGM) marker, flow-mediated di;atation (FMD)
- Secondary Outcome Measures
Name Time Method HbA1c, 1,5-AG, 8isoPGF2a, TBARS, total, LDL. HDL cholesterol triglyceride MDL and RLP cholesterol, AST ALT g-GTP LDH, BUN creatinine, cystatin C, urinary albumin excretion